In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 101 to 150 of 303

TitleTypeExpected publication date
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Technology appraisal guidance
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidanceTBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidanceTBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidance
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidanceTBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidanceTBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274Technology appraisal guidance
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Technology appraisal guidanceTBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Technology appraisal guidance
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidanceTBC
Glaucoma - lerdelimumab (CAT-152) [ID383]Technology appraisal guidanceTBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]Technology appraisal guidanceTBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Technology appraisal guidanceTBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Technology appraisal guidanceTBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidanceTBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidance
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Technology appraisal guidance
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459Technology appraisal guidanceTBC
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Iptacopan for treating complement 3 glomerulopathy ID6283Technology appraisal guidanceTBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981Technology appraisal guidance
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidance
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]Technology appraisal guidanceTBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Technology appraisal guidanceTBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]Technology appraisal guidanceTBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]Technology appraisal guidanceTBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863Technology appraisal guidanceTBC
Linzagolix for treating symptoms of endometriosis [ID6357]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]Technology appraisal guidanceTBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Technology appraisal guidanceTBC
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]Technology appraisal guidance
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All